Efficacy of oral consumption of curcumin/Curcuma longa for symptom improvement in inflammatory bowel disease:A systematic review of animal models and a meta-analysis of randomized clinical trials
作者机构:Programa de Pós-Graduacao em Nutricao(PPGNUT)Universidade Federal de Alagoas(UFAL)MaceióAL 57072-970Brazil Instituto de Química e Biotecnologia(IQB)Universidade Federal de Alagoas(UFAL)MaceióAL 57072-970Brazil Programa de Pós-Gradua玢o em Ciências da Saúde(PPGCS)Universidade Federal de Alagoas(UFAL)MaceióAL 57072-970Brazil Programa de Pós-Gradua玢o da Rede Nordeste de Biotecnologia(RENORBIO)Universidade Federal de Alagoas(UFAL)MaceióAL 57072-970Brazil Programa de Pós-Gradua玢o em Ciências Médicas(PPGCM)Universidade Federal de Alagoas(UFAL)MaceióAL 57072-970Brazil
出 版 物:《BIOCELL》 (生物细胞(英文))
年 卷 期:2022年第46卷第9期
页 面:2015-2047页
核心收录:
学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金:This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico(CNPq–Brazil)[Grant No.435704/2018-4] Fundacao de AmparoàPesquisa do Estado de Alagoas(FAPEAL)/PPSUS/Ministério da Saúde(MS)[Grant No.60030-000876/2016]
主 题:Ulcerative colitis Crohn’s disease Oxidative stress Curcuma Turmeric
摘 要:The roots of the vegetal Curcuma due to its high content of polyphenols,has been used successfully in several clinical *** review assessed the effect of curcumin/Curcuma longa on symptoms and metabolic changes in inflammatory bowel disease(IBD).A systematic review of animal models and randomized clinical trials(RCTs)was conducted by searching the following electronic databases:PubMed,CENTRAL,LILACS,Science Direct,and *** 997 found records,62 were *** than 90%of the animal studies reported an improvement in macroscopic,histologic and/or functional activity;80%identified decreased oxidative and/or inflammatory biomarkers in animals treated with *** the RCTs,intention-to-treat analysis showed that oral curcumin was effective in inducing clinical remission(n=281,RR:3.15 CI 95%[1.22–8.10]p=0.0017;i2=72.2%,p=0.006)and clinical response(n=259,RR:1.60 CI 95%[1.09–2.35]p=0.0017;i2=59.7%,p=0.042)but not endoscopic remission(n=161,RR:2.91 CI 95%[0.58–14.58]p=0.195;i2=72.7%,p=0.026).These results confirm that oral supplementation with curcumin/Curcuma longa has beneficial actions in animal colitis and,when associated with drug therapy,is effective in the treatment of patients with IBD.